Vertex Pharmaceuticals appoints Dr. Jenny Schneider to its Board as Independent Director

– USA, MA –  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the election of Dr. Jenny Schneider (M.D.) to its Board as an Independent Director, bringing the board to 11 members, of whom nine are independent.

“We’re thrilled to have Jenny join the Vertex Board. She brings a unique perspective and experience as a physician-executive with deep expertise in health systems, policy and reimbursement, as well as technology-enabled health care. As Vertex enters a new era of commercial diversification, Jenny’s decades-long work in population health and reimbursement, her data and analytical skills, and ability to apply emerging health technologies to complex problems will help Vertex fulfill its mission to serve more patients across new diseases and therapeutic modalities,” said Executive Chairman, Dr. Jeff Leiden.

About Dr. Jennifer Schneider

Dr. Jenny Schneider has more than two decades of experience as a physician, scientist, and healthcare executive in the healthcare industry. She co-founded and served as CEO of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Americans living in rural America. Before founding Homeward in 2022, Dr. Schneider served as President and CMO of Livongo Health, a biotechnology company serving people with chronic conditions including diabetes, hypertension, obesity, and behavioral health issues. While there, she led the company through history’s largest consumer digital health Initial Public Offering and the industry’s largest merger between Livongo and Teladoc Health. She also served as CMO of Castlight Health, a healthcare navigation company for self-insured companies.

“I am honored to join the Vertex Board at this incredibly exciting time in the company’s history with its commitment to innovation yielding extraordinary achievements in cystic fibrosis, sickle cell disease, and beta thalassemia, among others,” said Jennifer Schneider, M.D., M.S. “I look forward to working with my fellow directors to support the company’s continued innovation and growth.”

Before her industry roles, Dr. Schneider conducted research in health services at Stanford University and worked as a physician in internal medicine at various hospitals. She currently serves on the Board of Directors of Jasper Health and Maven Health.

Dr. Schneider holds a Bachelor of Arts in Biology from the College of the Holy Cross, a Doctorate in Medicine from Johns Hopkins University School of Medicine, and a Master of Science in health services research from Stanford University.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease, and transfusion-dependent beta-thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry’s top places to work, including 14 consecutive years on Science magazine’s Top Employers list and one of Fortune’s 100 Best Companies to Work.

SOURCE: www.vrtx.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.